• An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) unveiled a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete...
  • June 7, 2016 — Blue Earth Diagnostics Ltd. and Siemens’ PETNET Solutions Inc. announced the commercial availability of Axumin (fluciclovine F-18) injection in the United States.
  • A new Phase III clinical trial will look to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer.
  • cardio-oncology, echo strain assessment
    Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat cancer patients for the second leading cause of death among cancer survivors — cardiovascular disease brought on by their treatments.
  • MicroRNA molecules were discovered only relatively recently in humans, but have been shown to play a pivotal role in how a cell responds to injury or stress, such as radiation therapy. A University of California Los Angeles (UCLA)-led study has for the first time shown that microRNAs, specifically...
Accuray, Radixact Treatment Delivery Platform, image-guided radiation therapy, IGRT, FDA clearance
Technology | Image Guided Radiation Therapy (IGRT) | June 30, 2016
Accuray Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its...
blood test, PRRT, neuroendocrine tumors, NETs, somatostatin receptor imaging, SRI, SNMMI 2016 study

NET circulating transcript and chromogranin A (CgA) levels in responders and non-responders. a) Transcripts were significantly reduced at 6-month follow-up compared to pre-treatment values. Non-responders (NR) exhibited significantly elevated levels at 6 months (FUP_6m). This was also significantly higher than in responders (R). b) A significant alteration was noted only for CgA in non-responders (NR) at 6 months. c) Pre-PRRT: NET transcript scores were elevated in 94 percent and CgA in 57 percent. d) Responders: NET transcripts decreased in 88 percent of responders (no change in 12 percent). CgA was unchanged in 47 percent, decreased in 21 percent and was elevated in 32 percent. e) Non-Responders: NET transcripts increased in 90 percent (no change in 10 percent). CgA was unchanged in 33 percent, decreased in 40 percent and was elevated in 27 percent. For NET transcripts, no falsely decreased or increased values occurred in responders or non-responders, respectively. Credit: LuGenIum Consortium for Independent Research & Wren Laboratories

News | Oncology Diagnostics | June 23, 2016
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor...
neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016
Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering force linked to...
prostate cancer, biopsy, PET-CT, Ga-68 PSMA, SNMMI 2016 study, Wolfgang Fendler
News | PET-CT | June 20, 2016
Prostate cancer is the leading cancer among men, second only to skin cancer. With surgical removal at the frontline of...
pretargeted radioimmunotherapy, PIRT, colorectal cancer, radionuclide agents, SNMMI 2016, Sarah Cheal

Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody (e.g., huA33-C825 for detection and treatment of colorectal cancer) with dual specificity for a tumor-associated antigen (e.g., GPA33) and M-DOTA haptens (e.g., Lu-177 DOTA). Image courtesy of Memorial Sloan Kettering Cancer Center.

News | Radiopharmaceuticals and Tracers | June 20, 2016
An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of...
News | Prostate Cancer | June 17, 2016
Decatur Memorial Hospital, Decatur, Ill., is now offering C-11 choline positron emission tomography (PET)/computed...
immunotherapy, checkpoint inhibitors, University of Chicago study, radiation therapy, vaccination
News | Radiation Therapy | June 13, 2016
June 13, 2016 — By combining local radia...
UAB, iSR'obot Mona Lisa, prostate cancer, image-guided biopsy

Jeffrey Nix, M.D., left, and Soroush Rais-Bahrami, M.D., with the iSR’obotTM Mona Lisa , a new image guided device for diagnosing prostate cancer. Image courtesy of UAB News.

News | Biopsy Systems | June 09, 2016
The University of Alabama at Birmingham (UAB) announced it is one of two beta sites in the United States that will...
Fraunhofer MEVIS, radiation therapy efficiency, SPARTA project
News | Radiation Therapy | June 09, 2016
The Fraunhofer Institute for Medical Image Computing MEVIS in Bremen, Germany, recently completed a project to develop...
NaF-PET/CT, sodium fluoride, advanced prostate cancer, metastases, pilot study
News | PET-CT | June 07, 2016
A recent pilot study reported in the June issue of The Journal of Nuclear Medicine found that sodium fluoride (Na-F-18...
Axumin, fluciclovine F-18 injection, PET imaging agent, recurrent prostate cancer, Blue Earth Diagnostics, Siemens PETNET Solutions
Technology | Radiopharmaceuticals and Tracers | June 07, 2016
June 7, 2016 — Blue Earth Diagnostics Ltd. and Siemens’ PETNET Solutions Inc.
lung cancer, oliogometastases, progression-free survival, LCT, MD Anderson
News | Lung Cancer | June 06, 2016
Lung cancer patients with oliogometastases may benefit from aggressive local therapy, surgery or radiation, after...
News | Image Guided Radiation Therapy (IGRT) | June 06, 2016
Elekta and Philips announced the installation of a third high-field (1.5 Tesla) magnetic resonance-guided linear...
Novocure, METIS trial, Optune, Tumor Treating Fields, TTFields, NSCLC, lung cancer
News | Lung Cancer | June 03, 2016
June 3, 2016 — Novocure announced that the U.S.
Elekta, Leksell Gamma Knife Icon, Japan, United States, U.S. approval, radiosurgery system
News | Radiation Therapy | June 03, 2016
June 3, 2016 — Elekta announced that its Leksell Gamma Knife Icon...
prostate cancer, MRI, RSI, restriction spectrum imaging, tumor grade, UC San Diego study

The image on the left is a magnetic resonance image (MRI) of a prostate enhanced with restriction spectrum imaging (RSI). Higher grade tumor is indicated by orange and yellow. The image on the right is a digitized section of the prostate with the tumors outlined with blue dotted lines. Image courtesy of UC San Diego Health.

News | Prostate Cancer | June 02, 2016
June 2, 2016 — Physicians have long used...
University Hospitals Cleveland, proton therapy center, Mevion, Ohio
News | Proton Therapy | June 02, 2016
University Hospitals in Cleveland recently held a ceremony to mark the completion of its new $30 million proton therapy...
balloon catheter, IORT

The Xoft Axxent Controller, balloon and mini X-ray source assembled to simulate use during IORT. 

Feature | Women's Health | June 01, 2016 | By Barbara Schwartzberg, M.D., FACS
In recent years, intraoperative radiation therapy (IORT) has been growing in acceptance in the U.S. as an alternative...
MR-linac, MRI, linear accelerator

Elekta’s MR-linac combines two technologies — an MRI scanner and a linear accelerator — in a single system. This allows physicians to precisely locate tumors, tailor the shape of X-ray beams and accurately deliver doses of radiation evento moving tumors.

Feature | Radiation Oncology | June 01, 2016 | Jeff Zagoudis
As radiation therapy continues to evolve, new techniques and technologies are largely focused on maximizing the dose to...
prostate cancer, MRI, diagnosis, PRECISE trial, Canada
News | Prostate Cancer | June 01, 2016
A new Phase III clinical trial will look to evaluate if magnetic resonance imaging (MRI) can replace the current...
Overlay Init